BAJAJHCARE Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹165.66 Cr
verification pending
Revenue YoY
11.3%
reported change
EBITDA
₹29.6 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Bajaj Healthcare delivered a solid Q1 FY27 with revenue of ₹165.66 crore (+11.3% YoY) driven by 27% growth in domestic API and margin expansion to 17.8% EBITDA (+70bps YoY). Management guided to 10-15% revenue growth for FY27 and targets ₹900-1,000 crore revenue in 3-4 years. Key near-term catalysts include a 250kg peptide facility commissioning in Q4 FY27 (potential ₹200-300 crore peak revenue at 18-20% margins) and SEC recommendation for Syntocinomic tablets (₹10-12 crore FY27 opportunity). The export segment remains depressed at ~18% of revenue due to geopolitical headwinds, but six EU/UK DMF approvals position the company for FY28-29 commercialization. Management committed to ₹40-50 crore annual capex and flagged working capital efficiency (receivables at 131 days, targeting 110-120). Two loss-making Tarapur plants remain unsold. Risk: FY27 growth guidance of 10-15% appears modest given the high base and assumes stabilization in export revenues, which may prove optimistic if geopolitical conditions persist.
Colored figures show movement against the previous available record.
Guidance to track
- Management provided a specific growth range for FY27 revenue, stating 'the growth rate is around 10 to 15% for the next this year 2027'. The CFO confirmed similar growth rate expected for FY28.
- Management guided that margins will maintain 'mid to high teens level' going forward. In response to working capital question, CFO stated 'for FY 27 and 28 what kind of margin profile can we expect to maintain on a beta level 18 to 20%'.
- When asked about peak revenue from the 250kg peptide plant, management stated 'once we are to a peak and full utilization of plant we can expect anything around 200 to 300 crores of revenue and the margin would be around 18 to 20%'.
- Management committed to ongoing capital expenditure: 'the capex will be every year we are allocating around 40 to 50 crores for next every year it will be like 40 to 50 crores capital expenditure'.
Risks flagged
- Export contributed only ₹50.1 crore (~30% of revenue) vs historical levels. Management expects 'revenue mix to gradually normalize towards historical levels as export improves and geopolitical conditions ease'. If geopolitical tensions persist, the 10-15% growth guidance could be at risk.
- Three loss-making Tarapur plants were planned for divestment. Only one has been sold; two remain unsold. Management stated 'we are still on a lookout from a buyer' for the remaining units. Proceeds expected around ₹50 crore but timing remains uncertain, prolonging drag from loss-making operations.
- While the 250kg peptide facility targets Q4 FY27 commissioning, commercial revenue won't start until 2028 due to customer qualification and validation requirements. Management explicitly stated 'without plant commercialization nothing happens' and confirmed 'commercial revenues could start coming in in the second half of 28'. Near-term growth depends entirely on existing businesses.
- The MOU with ICT for fermentation-based vitamin C manufacturing 'will be a patented technology' but management acknowledged 'this is a long long way to go' with completion expected in 2029. This 8-9% revenue product faces continued import dependency for ~3+ years.
Key quotes
- We are the first company in India to secure SEC recommendation for manufacturing and marketing of syntocinomic tablets and we have also successfully completed the BE studies of surinent tablets and are processing towards the regulatory approval procedures.
- The growth rate is around 10 to 15% for the next this year 2027. We can expect 18 to 20% margin profile to maintain on a beta level going forward.
- Once we are to a peak and full utilization of plant we can expect anything around 200 to 300 crores of revenue and the margin would be around 18 to 20%.
- We have already filed a DMF in UK and Europe and we have already got six CP approval recently over period of in last 6 to 8 months. The first batch of revenue can be expected in FY 28-29.
Research modules